|
楼主 |
发表于 2008-12-10 09:53:51
|
显示全部楼层
68-5-第五节 血管炎的诊断与治疗
系统性血管炎的临床表现复杂多样且无特异性,故给临床诊断带来一定的困难。系统性血管炎需根据临床表现、实验室检查、病理活检资料以及影像学资料包括 X一线胸片、血管造影、CT, MRI等综合判断,以确定血管炎的类型及病变范围。如出现无法解释的下列情况时,应考虑血管炎的可能:①多系统损害。②进行性肾小球肾炎或血肌ffF和尿素氮进行性升高。③肺部多变阴影或固定的阴影/空洞。④多发性单神经根炎或多神经根炎。⑤不明原因发热。⑥缺血性或淤血性症状。⑦紫瘫性皮疹或网状青斑。⑧结节性坏死性皮疹。⑨无脉或血压升高。⑩不明原因的耳鼻喉或眼部病变。)ANCA,AECA阳性。此外,在作出血管炎诊断时应除外感染、肿瘤以及弥漫性结缔组织病,如系统性红斑狼疮、类风湿关节炎、干燥综合征等。
& \2 G* @; S* H: Q; e; ]8 c" o
$ Q n+ U6 I; B* R5 J' w0 I, r( i 血管炎的治疗原则是早期诊断、早期治疗,以防止不可逆的损害。患者一旦确诊为血管炎,就应积极治疗,即使尚未明确分型,以免因分型而延误病情,贻误治疗时机。血管炎的常用治疗药物为糖皮质激素和免疫抑制剂,后者以环磷酞胺最为常用。部分血管炎,如川崎病使用IVIg(静脉用丙种球蛋白)具有良好效果。其他还可试用血浆置换。近年来,不断地有新的生物制剂用于临床。抗感染治疗在韦格纳肉芽肿的治疗中具有作用。各种血管炎的具体治疗方法见各论。 6 i/ I( A7 t1 @ S4 U* b
8 }1 H3 Q( J1 s( @) ]* N# _ 为了评估血管炎的病情活动情况,各国学者制定了不少评分标准,较常用的有系统性坏死性血管炎的伯明翰评分 (Birmingham vas-culitis activity score, BVAS) ,Olsen等制定的血管炎活动指数(Vasculitis activity index, VAI)和Kallenberg等制定的韦格纳肉芽肿的疾病活动评分标准(Criteria for disease activity in We-gener' s granulomatosis) o这些评分标准用于评估病情和预后,指导治疗。血管炎在合并感染以及并发其他疾病时,临床表现可以类似于病情活动,为区别于病情本身的活动,可采用BVAS进行评估,也具有指导意义。以下给出BVAS评分系统。
; U# A1 @/ n6 R+ z' T. r, n4 ?+ a" X2 K$ B; x" s
伯明翰系统性血管炎活动评分(Birming-ham vasculitis activity score, BVAS): / L+ s. u" \1 o5 e, S* N
' I% W% u0 G% Y$ T& D0 y2 L2 h 参考文献:2 N7 q1 o, t8 K) l
u# P0 o6 x6 r; C# Y7 F- g Audrian M P, Baranger T A R, Moguilevski N, et al. Antinative and recombinant myeloperoxidase monoclonals and humanantibodies. Clin Exp Immunol 1997. 107:127一134 9 l {3 a) F8 O; w& Y B
/ \+ L$ e6 p# _, {( M Brasile L, Kremer J M, Clarke J L, et al. Identification ofan autoantibody to vascular endothelial cell-specific antigens in pa-tients with systemic vasculitis. Am J Med,1989. 87:74一80
; k* J* [/ p [7 {9 o. L6 J7 P% b8 k9 h' W% p$ Q1 U
Chan T M, Frampot G, Jayne D R W, et al. Clinical signif-icance of anti-endothelial cell antibodies cell antibodies in systemicvasculitis: a longitudinal study comparing anti-endothelial cell an-tibodies and anti-neutrophil cytoplasm antibodies. Am J KidneyDis,1993. 22:387一392 ) m _1 T6 K8 {: w2 t6 o( z
, S7 T3 s8 ?. }% ~/ n. X- n; E
Churg J, Strauss L. Allergic granulomatosis, allergic angi-itis, and periarteritis nodosa. Am J Patho1,1951.27: 277一301
/ m, j! J" ?; e. {* `, ^2 R$ J5 a( k8 E; v0 N: |! L
Erihhorn J, Sima D, Thiele B, et al. Anti-endothelial cellantibodies in Takayasu arteritis. Circulation, 1996. 94: 2396一2401
* Y8 \) M7 d0 I" n" z2 P
0 I8 S9 k& f8 o( t K0 r) T6 N% w; M Ewert B H, Jennette J C, Falk R J, et al. Antibodies a-gainst myeloperoxidase stimulate primed neutrophil to damage hu-man endothelial cell in vitro. Kidney Int,1992. 41:375一383 ( D) e! \5 C0 D6 [. A
1 |/ n2 I% _+ ^/ A Z: ]% h
Falk R J, Terrell R S, Charles L A, et al. Anti-neutrophilcytoplasmic autoantibodies induced neutronphils to degranulateand produce oxygen radical in vitro. Proc Natl Acid Sci USA,1990.87:4115一4119
1 X6 E: w! J* c7 x Frank M M, Basta M, Fries L F. The effects of intravenousimmune globulin on complement-dependent immune damages ofcells and tissues. Clin Immunol Immunopathol,1992.62:S82一86
" p5 @2 w8 i7 R$ y) [3 e K8 \% `5 a, w4 ^( H6 A: z
Fujeda M, Oshi N, Kurashige T. Antibodies to aendothelialcells in Kawasaki disease lyse endothelial cells without cytokinepretreatment. Clin Exp Immuno1,1997. 107: 120一126
( c3 F+ Y0 Z* E/ ^) c2 w
: ]3 `- j; ^1 {2 L( @ ?( H( n# @) B Gdbel U, Erichhorn J, Kettriz R, et al. Disease activity andautoantibodies to endothelial cells in patients with Wegener' sgranulomatosis. Am J Kidney Dis,1996. 28: 186一194
~, \- U+ R4 z% C- H$ j8 g* s& A; a1 d. B. O$ T9 ?; ~2 @. R
Haynes B F. Vasculitis: Pathogenic mechanisms of vesseldamage. In: Gallin JI, Goldstein IM, Snyderman R, eds. In-flammation: basic principles and clinical correlates. New York:Raven Press, 1992.921一941
, L. Y( k; l% `) s
3 C/ J. l: D( e6 F* D: Y6 S Hoffman D S. Vasculitis syndromes: editorial overview.Curr Opin Rheumato1,1994. 6:1一2 h) t2 V2 x9 U7 n
5 x; t) e) |) X* K. n9 D
Hunder G G, Arend W P, Bloch DA, et al. The AmericanCollege of Rheumatology 1990 criteria for the classification of vas-culitis. Introduction. Arthritis Rheum, 1990. 33:1065一1067 - r1 Z- {+ k; n0 M3 s& }
2 ~: |) z4 @' H4 z( o Jennette J C, Falk R J, Andrassy K, et al. Nomenclature ofsystemic vasculitides. Proposal of an international consensus con-ference. Arthritis Rheum, 1994. 37:187一192 , P% R# C& J. `) B
& S) Q% A" P9 C4 W+ Q
Jennette J C, Falk R J. Small vessel vasculitis. N Engl JMed, 1997.337:1512一1513
6 }' G* f& j; y/ ~9 r; N' j. e* z Y8 L, \+ b
Kammer G M, Soter N A, Schur P H. Circulating immu-nune complexes in patients with necrotizing vasculitis. Clin Immunol Immunopatho1,1980. 15:658一672
7 N% I, n6 A& z; V- E" x- e+ _& h+ {* [6 e- ]1 U* V1 I
Kaneko K, Savage C O S, Pottinger B E, et al. Antien-dothelial cell antibodies can be cytotoxic to endothelial cells with-out cytokine pre-stimulation and correlate with ELISA antidodymeasurement in Kawasaki disease. Clin Exp Immuno1,1994. 98:264一269
7 c3 K- [# o) X/ u' @
1 f8 Q0 ~, s0 k Lie J T. Nomenclature and classification of vasculitis: Plus cachange, plus c' est la meme chose. Arthritis Rheum, 1994. 37:181一186 + u: D2 E' Y2 W, i, h; b) _
_) b4 U8 b! E, j$ y' p8 h Lockwood C M, Thiru S, Isaacs J D, et al. Long-term ree-mission of intractable systemic vasculitis with monoclonal antibodytherapy. Lancet, 1993. 341:1620一1622 % ]9 D4 f \; W& e
" I$ g, F/ h1 L7 {( [ Luqmani R A, Bacon P A, moots R J, et al. Birminghamvasculitis activity score (BVAS) in systemic necrotizing vasculitis.Q J Med,1994.87:671一678 ! [) j: M$ t$ D
5 f6 f2 ?0 b7 s C McCluskey R T, Fienberg R. Vasculitis in primary vasculi-tides, granulomatoses, and connective tissue disease. HumPathol,1983. 14:305一315
* r4 t. B6 j! d0 H+ `
6 Z& I. R) n$ C Papa N D, Guidall L, Sironi M, et al. Anti-endothelial cellIgG antibodies from patients with Wegener's Granulomatosis bindto human endothelial cells in vitro and induce adhesion moleculeexpression and cytokine secretion. Arthritis Rheum, 1996. 39:758一766 : `4 L5 p7 h2 \. x
, t* S/ q8 z+ {7 I
Prapromik S, Blank Miri, Meroni P, et al. Classification ofanti-endothelial cell antibodies into antibodies against microvascu-lar and macrovascular endothelial cell. Arthritis Rheum, 200144:1484一1494
/ s/ k1 v: I2 D! `" L+ r8 R" L9 \$ i2 m& N4 k$ u$ v# [& P) Y7 `
Savage C O S, Pottinger B E, Gaskin G, et al. Vasculardamage in Wegener's granulomatosis and microscopic polyarteri-tis: Presence of Antiendothelial cell antibodies and their relation toanti-neutrophil cytoplasm antibodies. Clin Exp Immunol, 1991.85:14一19
6 q/ }+ O5 [. }5 A7 Y* v% Z# {1 p, N. |6 \" o
Savage C O S, Pottinger B E, Gaskin G, et al. Autoanti-bodies developing to myeloperoxidese and proteinase 3 in systemicvasculitis stimulate neutronphil cytotoxicity toward cultured en-dothelial cells. Am J Pathol,1992. 41:375一383
* ]3 k# J1 B+ }% R$ s- S- S0 I/ T f& W8 k% V
Schifferli J A, Yin C N, Peters D K. The role of comple-ment and its receptor in the elimination of immune complexes. NEngl J Med,1986. 315:488一495 : x6 z3 _. y+ h1 X- y# H
0 U% ]) `- ~$ E Wegener F, iiber generalisiete, septische gefasserkrankungen.Verb Dtsch Ges Pathol,1936. 29:202一210
1 b' d( n% R" h# ^* t Westphal J R, Boerbooms A M T H, Schalkwijk C J M, etal. Anti-endothelial cell antibodies in sera of patients with autoim-mune diseases: comparison between ELISA and FACS analysis.Clin Exp Immuno1,1994. 96:444一449 , F) g( _% E9 i$ k8 L8 p
4 V/ [# f9 l# F! t& a Zeek P M. Periarteritis nodosa: a critical review. Am JPathol,1951.22:777一79。 |
|